

Jasmanda Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2082171/publications.pdf>

Version: 2024-02-01

10
papers

116
citations

1477746

6
h-index

1473754

9
g-index

10
all docs

10
docs citations

10
times ranked

215
citing authors

#	ARTICLE	IF	CITATIONS
1	Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2384-2393.	2.2	25
2	Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2123-2132.	2.2	24
3	The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program â€“ Current Status and Future Direction. <i>Clinical Therapeutics</i> , 2016, 38, 2526-2532.	1.1	17
4	Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm. <i>Cancer Epidemiology</i> , 2015, 39, 242-249.	0.8	16
5	Early hypoglycaemia and adherence after basal insulin initiation in a nationally representative sample of Medicare beneficiaries with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2486-2495.	2.2	10
6	Assessment of Dronedarone Utilization Using US Claims Databases. <i>Clinical Therapeutics</i> , 2014, 36, 264-272.e2.	1.1	7
7	Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study. <i>Advances in Therapy</i> , 2020, 37, 3863-3877.	1.3	7
8	How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 <sc>U/mL</sc> in a real-world setting?. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 838-843.	2.2	5
9	Clinical outcomes in high-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, 5, e00306.	1.0	5
10	Abstract 18020: Identifying Hospitalizations Related to Heart Failure in Dronedarone Users Who Are Supplementary Medicare Beneficiaries. <i>Circulation</i> , 2014, 130, .	1.6	0